Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The choice of neoadjuvant chemotherapy regimen for locally advanced gastric cancer is controversial. The aim of this study was to compare the short- and long-term outcomes of XELOX regimen with Docetaxel, S1 and oxaliplatin regimen as neoadjuvant chemotherapy regimen for locally advanced gastric cancer. The objective of this study is to determine what kind of neoadjuvant chemotherapy strategy can make subsequent radical surgery feasible and improve overall survival in patients with locally advanced gastric cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianshu Liu
• Treatments: Capecitabine; Docetaxel; Oxaliplatin; Tegafur

Criteria

Inclusion Criteria:

• patients with unresectable, histologically confirmed gastric adenocarcinoma with no distant metastases were eligible for the study.

Exclusion Criteria:

• peritoneal metastasis confirmed by CT scan

• lung metastasis, liver metastasis, pleural effusion, and/or other distant metastasis

• serious uncontrolled co-morbid conditions

• lacking of measurable target lesion

• any local intervention after initial diagnosis, such as surgical procedures, radiotherapy or trans-artery chemo-embolization

• patients who could not comprehend or comply with the study were also ineligible.